Arrowhead Pharmaceuticals (ARWR) Accumulated Depreciation & Amortization: 2010-2025
Historic Accumulated Depreciation & Amortization for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $6.0 million.
- Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization rose 30.43% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 31.36%. This contributed to the annual value of $22.2 million for FY2025, which is 31.36% up from last year.
- According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization is $6.0 million, which was up 3.45% from $5.8 million recorded in Q2 2025.
- In the past 5 years, Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization registered a high of $6.0 million during Q3 2025, and its lowest value of $1.5 million during Q1 2021.
- In the last 3 years, Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $4.4 million in 2024 and averaged $4.3 million.
- Data for Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization shows a peak YoY soared of 86.36% (in 2024) over the last 5 years.
- Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $2.1 million in 2021, then rose by 9.52% to $2.3 million in 2022, then skyrocketed by 65.22% to $3.8 million in 2023, then climbed by 26.32% to $4.8 million in 2024, then skyrocketed by 30.43% to $6.0 million in 2025.
- Its Accumulated Depreciation & Amortization was $6.0 million in Q3 2025, compared to $5.8 million in Q2 2025 and $5.6 million in Q1 2025.